World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
54975
World Ranking
2735
National Ranking
1527

Harry W. Herr publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Harry W. Herr sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 663 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Harry W. Herr D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Harry W. Herr sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Harry W. Herr is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine with significant contributions in surgery, urology, molecular biology, epidemiology, and oncology. The main areas of study concentrate on bladder and urothelial cancer treatments, urinary and genital oncology studies, urological disorders and treatments, epigenetics and DNA methylation, urinary bladder and prostate research, pediatric urology and nephrology studies, and cancer immunotherapy and biomarkers.

The scientist has published extensively in several venues, with the highest number of publications appearing in The Journal of Urology, followed by the Journal of Clinical Oncology, Urology, Urologic Oncology Seminars and Original Investigations, and the Journal of the National Comprehensive Cancer Network.

Frequent coauthors collaborating with Harry W. Herr include Bernard H. Bochner, S. Machele Donat, Guido Dalbagni, Eugene J. Pietzak, and K. Eugene, reflecting a network of professionals working in related fields.

Some of the recent papers authored or coauthored by Harry W. Herr include:

  • Bladder Cancer, Version 3.2020, published in 2020 in the Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022, published in 2022 in the Journal of the National Comprehensive Cancer Network
  • Bladder Cancer, Version 3.2024, published in 2024 in the Journal of the National Comprehensive Cancer Network
  • Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial, published in 2022 in the Journal of Clinical Oncology
  • Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma, published in 2023 in the Journal of Clinical Oncology

Best Publications

  • Epidemiology and risk factors of urothelial bladder cancer

    Maximilian Burger;James W.F. Catto;Guido Dalbagni;H. Barton Grossman

  • Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology

    Ahmad Shabsigh;Ruslan Korets;Kinjal C. Vora;Christine M. Brooks

  • Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

    Donald L. Lamm;Ad P.M. Van Der Meijden;Alvaro Morales;Stanley A. Brosman

  • Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

    Harry W. Herr;Bernard H. Bochner;Guido Dalbagni;S. Machele Donat

  • Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

    Cora N. Sternberg;Alan Yagoda;Howard I. Scher;Robin C. Watson

  • Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy

    Dean F. Bajorin;Paul M. Dodd;Madhu Mazumdar;Melissa Fazzari

  • The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome

    Michael S. Cookson;Harry W. Herr;Zuo Feng Zhang;Scott Soloway

  • Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report

    Harry W. Herr;James R. Faulkner;H. Barton Grossman;Ronald B. Natale

  • Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression

    Alvaro S. Sarkis;Guido Dalbagni;Carlos Cordon-Cardo;Zuo-Feng Zhang

  • THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORS

    Harry W. Herr

  • Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial

    Bernard H. Bochner;Guido Dalbagni;Daniel D. Sjoberg;Jonathan Silberstein;Jonathan Silberstein

  • CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

    Padmanee Sharma;Yu Shen;Sijin Wen;Sachiko Yamada

  • M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

    Cora N. Sternberg;Cora N. Sternberg;Alan Yagoda;Alan Yagoda;Howard I. Scher;Howard I. Scher;Robin C. Watson;Robin C. Watson

  • DOES EARLY CYSTECTOMY IMPROVE THE SURVIVAL OF PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS

    Harry W. Herr;Pramod C. Sogani

  • PARTIAL NEPHRECTOMY FOR UNILATERAL RENAL CARCINOMA AND A NORMAL CONTRALATERAL KIDNEY: 10-YEAR FOLLOWUP

    Harry W. Herr

  • Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care.

    Alice B. Kornblith;Harry W. Herr;Ursula S. Ofman;Howard I. Scher

  • Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

    D F Bajorin;M F Sarosdy;D G Pfister;M Mazumdar

  • Bladder cancer. Clinical practice guidelines in oncology.

    Peter E. Clark;Neeraj Agarwal;Matthew C. Biagioli;Mario A. Eisenberger

  • Superiority of Ratio Based Lymph Node Staging for Bladder Cancer

    Harry W. Herr

  • History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story

    Harry W. Herr;Alvaro Morales

Frequent Co-Authors

Guido Dalbagni
Guido Dalbagni Memorial Sloan Kettering Cancer Center
Bernard H. Bochner
Bernard H. Bochner Memorial Sloan Kettering Cancer Center
Willet F. Whitmore
Willet F. Whitmore Memorial Sloan Kettering Cancer Center
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
William R. Fair
William R. Fair Memorial Sloan Kettering Cancer Center
Victor E. Reuter
Victor E. Reuter Memorial Sloan Kettering Cancer Center
Paul Russo
Paul Russo Memorial Sloan Kettering Cancer Center
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Hikmat Al-Ahmadie
Hikmat Al-Ahmadie Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine in the USA isn't limited to traditional medical school. Numerous affordable online programs now allow students to enter healthcare roles or advance their education, often while working or balancing other commitments. For those beginning their journey, the cheapest online bsn programs provide a flexible route to earning a Bachelor of Science in Nursing, which is the foundation required for many clinical jobs.

Registered nurses seeking to expand their qualifications may consider the rn to bsn online pathway. This is designed specifically for working RNs needing an affordable and convenient way to obtain a BSN. Similarly, nurses aiming for leadership roles or advanced clinical positions can look into the cheapest online np programs, which train nurse practitioners who play a critical role in modern healthcare.

For those interested in research, teaching, or executive-level leadership, the cheapest phd nursing programs make it possible to earn a doctorate online. Exploring these online degree options is a smart step for anyone considering the many dynamic career pathways related to medicine in the USA.

Best Scientists Citing Harry W. Herr

Trending Scientists

Recently Published Articles